logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJob offers
 

News

boto imprimir
Date: 28/11/2013

Why tumors become resistant to chemotherapy?

IDIBELL Researchers describe epigenetic changes that explain the lack of response to drugs in colon cancer


A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance", but today the group of Manel Esteller, Director of Epigenetics and Cancer Biology at the Bellvitge Biomedical Research Institute (IDIBELL), ICREA researcher and Professor of Genetics at the University of Barcelona, describes in the official Journal of the National Cancer Research Center in the United States, The Journal of The National Cancer Institute, the existence of epigenetic differences that explain the lack of response of the tumor recurs.

 

"We studied colon cancer cells that were initially sensitive to oxaliplatin drug and then became insensitive to this drug and we found that resistant tumors had inactivated a gene (SRBC) in their DNA" says Manel Esteller "the loss of activity supposedly happens in a gene involved in DNA repair. Thus these tumor cells, when receiving the drug, quickly repair the effect thereof and do not die. Studying nearly two hundred patients with colon cancer also found that inactivation of the gene is associated with poorer survival of these people despite treatment. Interestingly the loss of function of this gene could also explain why some colon tumors are resistant from the outset, what is known as “primary resistance " concludes Esteller.

 

The discovery could have important implications for personalized treatment of colon cancer. If these findings extend to other clinical trials, determining the activation state of the SRBC gene could be useful in deciding whether a patient should receive a type of drug or another. Likewise the use of another class of drugs that return gen activity (epigenetic drugs) could restore the sensitivity to the original drug , oxaliplatin .

 

Finally, a very promising door is opened to examine whether similar mechanisms are happening in other human tumors beyond colon cancer.

 

Article reference

 

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. Moutinho C, Martinez-Cardús A, Santos C, Navarro-Pérez V,  Martínez-Balibrea E, Musulen E, Carmona FJ, Sartore-Bianchi A, Cassingena A, Siena S, Elez E, Tabernero J, Salazar R, Abad A, Esteller M. The Journal of the National Cancer Institute, PMID: 24273214, 2013.





foto Microscopic image of a colon cancer
Microscopic image of a colon cancer

Share/Bookmark
 
© 2014 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




You have not yet answered the Human Resources Strategy for Research survey. It will not take you more than five minutes. Your opinion is very important to improve IDIBELL.

Do you want to complete the survey now?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No